CAMBRIDGE, Mass.--(BUSINESS WIRE)--Elixir Pharmaceuticals, Inc. announced today that its partner, Siena Biotech S.p.A., has commenced Phase 1 clinical testing of Elixir’s potent, first-in-class SIRT1 (sirtuin-1) inhibitor for the treatment of Huntington’s Disease. EX-527, also known as SEN0014196, is currently in a Phase 1a combined single and multiple ascending dose study in the European Union to assess safety, tolerability and pharmacokinetics in healthy volunteers.
